Momelotinib is an oral JAK1/JAK2/ACVR1 inhibitor approved in September 2023 for the treatment of patients with MF and anemia and is designed to address the complex drivers of iron-restricted anemia and inflammation associated with MF [5,13]. This evidence concerns the gene ACVR1 and anemia (phenotype).